EIPICO’s consolidated profit hikes 34.5% YoY in 6 months
Updated 8/10/2022 10:39:00 AM
Arab Finance: The Egyptian International Pharmaceutical Industries Company (EIPICO) (PHAR) registered a consolidated net profit attributable to the holding company of EGP 283.25 million in the first half (H1) of 2022, up by 34.58% from EGP 210.47 million in H1 2021, according to the consolidated financial income statement filed to the Egyptian Exchange (EGX) on August 10th.
The company achieved net sales of EGP 1.73 billion in the six-month period ended June 30th, compared to EGP 1.54 billion in the same period a year earlier.
According to the standalone financial income statement, EIPICO recorded a standalone net profit after tax of EGP 297.59 million in H1 2022, compared to EGP 244.99 million in H1 2021.
Founded in 1980, EIPICO is an Egypt-based public shareholding company that operates in the pharmaceutical industry. It is a manufacturer and exporter of pharmaceuticals and holds license agreements with a group of international.
